Press Release
AB-Therapeutics participates in the 10th Venture Capital Forum NEOTEC
AB-Therapeutics, located at the UAB Research Park, will have the opportunity to meet investors and secure funding for the development of new drugs for the treatment of lung cancer and pancreatic cancer.
The 10 th NEOTEC Venture Capital Forum is a forum where investors and technology companies in funding rounds meet. AB-Therapeutics has been one of the 15 companies selected to participate in this forum, where they will have the opportunity to present their project to potential investors.
AB-Therapeutics is seeking investors for its first round of funding. 85% of the funds will be invested in the preclinical and clinical development of drug candidates to treat lung cancer and pancreatic cancer, through outsourcing to contract research organizationa (CRO). Only 15% of the costs will be allocated to overhead and human resources.
The spin-off has a new therapeutic approach for cancer of the lung and pancreas, Multitarget Lipid Signaling, which alters the dynamics of multiple proteins in the cell membrane and has a much lower toxicity compared to classical chemotherapy.
NEOTEC Venture Capital Forum will be held on November 10 in La Rioja, organized by the Center for Industrial Technological Development (CDTI), the Economic Development Agency of La Rioja and RedOTRI, and collaboration, among others, ACC1Ó and the Association of Technology Parks of Spain (APTE).
The 10 th NEOTEC Venture Capital Forum is a forum where investors and technology companies in funding rounds meet. AB-Therapeutics has been one of the 15 companies selected to participate in this forum, where they will have the opportunity to present their project to potential investors.
AB-Therapeutics is seeking investors for its first round of funding. 85% of the funds will be invested in the preclinical and clinical development of drug candidates to treat lung cancer and pancreatic cancer, through outsourcing to contract research organizationa (CRO). Only 15% of the costs will be allocated to overhead and human resources.
The spin-off has a new therapeutic approach for cancer of the lung and pancreas, Multitarget Lipid Signaling, which alters the dynamics of multiple proteins in the cell membrane and has a much lower toxicity compared to classical chemotherapy.
NEOTEC Venture Capital Forum will be held on November 10 in La Rioja, organized by the Center for Industrial Technological Development (CDTI), the Economic Development Agency of La Rioja and RedOTRI, and collaboration, among others, ACC1Ó and the Association of Technology Parks of Spain (APTE).
LATEST NEWS
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
07.10.2022
Press Release
AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022
Press Release
Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022
Press Release
AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
13.06.2022
Press Release
AbilityPharma Will Attend the ESMO Gynaecological Cancers Congress 2022 in Valencia + info